local_hospital

St. Olavs Hospital HF

Address
lock Available on a paid plan

Hemic and Lymphatic Diseases

At St. Olavs Hospital HF, the Rheumatology department contributes to research in hematologic cancers and related blood disorders, with trials focused on follicular lymphoma and diffuse large B-cell lymphoma. These studies are designed to evaluate how well new treatment approaches control disease and improve outcomes for patients with relapsed or difficult-to-treat lymphoma.

  • Testing new therapy options for follicular lymphoma
  • Comparing treatment effectiveness in diffuse large B-cell lymphoma
  • Studying approaches for early relapse and refractory disease

The site’s work in this area reflects a strong interest in finding better ways to manage lymphatic system cancers and support patients whose disease returns after initial treatment.

Musculoskeletal Diseases

Research in musculoskeletal diseases centers on osteoarthritis, especially painful inflammatory disease in the first carpometacarpal joint. These trials aim to compare symptom relief strategies and improve everyday function for people living with hand arthritis.

  • Evaluating treatments for painful inflammatory osteoarthritis
  • Comparing intraarticular corticosteroid care with other supportive options
  • Assessing non-drug rehabilitation approaches for joint pain

This work at St. Olavs Hospital HF highlights a practical focus on easing pain, preserving mobility, and identifying the most effective care for common joint disorders.

Neoplasms

Within the broader field of neoplasms, the site is involved in trials for non-small cell lung cancer and atypical teratoid/rhabdoid tumours. The research includes efforts to test new cancer therapies and to improve survival outcomes in both adult and pediatric oncology.

  • Investigating treatment effectiveness in non-small cell lung cancer
  • Studying consolidation strategies for atypical teratoid/rhabdoid tumours
  • Exploring better ways to improve survival in aggressive cancers

These studies show an interest in both solid tumors and rare childhood cancers, with a clear goal of advancing more effective cancer care.

Nervous System Diseases

The site also supports research in nervous system diseases, with a strong emphasis on migraine and chronic migraine. The trials are aimed at confirming whether preventive treatment strategies can reduce headache burden and improve daily life for people affected by recurrent migraines.

  • Studying prevention for chronic migraine
  • Evaluating treatment options for episodic migraine
  • Measuring the impact of therapies on headache frequency and symptom control

This area of research focuses on better long-term management of migraine disorders, an important need for patients with frequent or disabling headaches.

Virus Diseases

In virus diseases, clinical trials at St. Olavs Hospital HF address COVID-19 and mpox virus disease. The studies examine whether antiviral or immune-targeted treatments can improve recovery, reduce complications, and support hospitalized patients with active infection.

  • Evaluating treatment effectiveness in SARS-CoV-2 infection
  • Assessing care strategies for hospitalized patients with moderate and severe COVID-19
  • Describing outcomes in mpox virus disease with and without antiviral treatment

This infectious disease research reflects a focus on improving care during outbreaks and identifying therapies that may lessen the impact of serious viral illness.

Site Overview

assignment
16
connected trials
corporate_fare
12
sponsors
science
39
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
16
Total trials linked
Highly Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 6 therapeutic areas and 15 of 39 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
10
Sponsors (total)
12
Active sponsors
7

Sponsor Network

Top 7 by active trials.

lock +6 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +1 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 112 other sites in Norway

description
Trial volume
16
Outperforms 86% of sites
public
Therapeutic diversity
6areas
Outperforms 79% of sites
groups
Sponsor diversity
12sponsors
Outperforms 84% of sites

Therapeutic Area Benchmark — Norway

Select a therapeutic area to compare against other sites in Norway.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Norway

Market Share

Country: Norway

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in St. Olavs Hospital HF

lock Showing 1 of 16 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A multicentre, triple blind, placebo controlled, parallel group study of atorvastatin in chronic migraineSt. Olavs Hospital HFPhase IINot Yet Recruiting

IMP list

lock Showing 1 of 39 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Atorvastatin4Unknown2024-05-132024-05-13

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.